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Establishing and
Coordinating a
Nationwide
Multidisciplinary Study
Group: Lessons Learned
by the Dutch Pancreatic
Cancer Group
R esearchers are increasingly interested injoining forces in multicenter, multidisci-
plinary study groups as a means to conduct
high-quality research, including large ran-
domized trials and prospective cohorts with
the aim to improve the quality of care. In the
Netherlands, clinical care and research in
pancreatic diseases are well-organized within
the nationwide Dutch Pancreatitis Study
Group and, since 2011, the Dutch Pancreatic
Cancer Group (DPCG). The Netherlands has
some inherent benefits for multicenter col-
laboration, including a small and densely
populated country (17 million inhabitants),
full-time PhD-students working for 3–4
years in clinical research before applying
for a residency position, and a healthcare
system that pays per diagnosis rather than
per intervention allowing for comparisons
between procedures/strategies. Aside from
this specific situation in the Netherlands,
we feel that the presented model of nation-
wide study groups is also applicable to other
regions and countries.
No clear guidance exists on how to
establish a multidisciplinary study group. In
recent years, several members of our group
have been asked to share their experiences
during (inter-)national meetings. To provide
a framework for those interested in multicen-
ter collaboration, we herewith outline the
establishment and coordination of the nation-
wide DPCG, and many of our lessons learned
over the past eight years.
ESTABLISHING A MULTICENTER
STUDY GROUP
The DPCG is a nationwide collabora-
tion of surgeons, clinicians from other medi-
cal specialties, researchers, nurses, and
patient associations involved in pancreatic
and periampullary cancers and neoplastic
cysts. All 16 hospitals performing pancreatic
surgery and several hospitals providing non-
surgical care for pancreatic cancer patients in
the Netherlands participate. The DPCG was
founded with the aim to improve care and
survival for patients with pancreatic cancer
and built on previous experiences of the
Dutch Pancreatitis Study Group.
The first prerequisite is a group of
experts who are willing to collaborate within
a culture of commitment and mutual trust. All
should strongly feel that morewill be achieved
by collaboration than by competition.Willing-
ness to compromise and take turns in the lead
of projects are essential. The board of the study
group should facilitate this by showing the
right example and arranging transparent regu-
lations supporting the group rather than the
individual. Deciding on a group name and
logo, soon to be followed by a house style
for PowerPoint presentations and a basic web-
site early in the process may seem trivial but
are important to promote the ‘‘group feeling.’’
Funding the start-up of such an initiative may
be difficult but is essential. The DPCG board
approached possible sponsors (industry and
patient organizations) to compile a small start-
ing budget. During the first years, a small
budget per year was sufficient.
BUILDING A MULTICENTER
STUDY GROUP
The three main ‘‘platforms’’ within the
DPCG are the plenary study group, and the
scientific committee, and the board (Fig. 1).
During the four plenary study groupmeetings
per year, new proposals for prospective clini-
cal studies (including randomized trials), and
progress of ongoing studies are discussed.
Hence, commitment and input from all par-
ties are enhanced. Moreover, new develop-
ments in pancreatic cancer from conferences
and literature, and the outcome of the surgical
and other audits are discussed.
The scientific committee consists of
25 representatives from different specialties,
a legal advisor, a clinical epidemiologist and
a representative from the patient association.
This committee meets four times per year
to evaluate research proposals for the use of
data from the clinical registries, biobank, and
completed trials1,2; advises on scientific
activities, including the yearly reporting of
the mandatory surgical audit; and assesses
research grant applications which are sub-
mitted on behalf of the DPCG.
Researchers interested in using data
from the registries, biobank, and trials can
download a protocol template with instruc-
tions from the DPCG-website (www.dpcg.nl)
and send the request to the DPCG-coordina-
tor who disperses it before the scientific
committee meeting. Subsequently, the
researcher is invited to briefly explain his/
her proposal at the meeting and take part in
the discussion. The proposal may either be
approved (with adjustments) or rejected,
mostly with the option to resubmit. The
aim of the scientific meeting is to promote
high-quality research and prevent overlap-
ping initiatives, rather than function as a
judgmental organ.
The DPCG board consists of represen-
tatives from surgery, medical oncology,
gastroenterology, radiotherapy, and the
patient association. In their 4-monthly meet-
ings, the board, supported by a PhD-student
and the ‘‘DPCG-coordinator’’ (ie, a dedi-
cated research nurse), discusses general
issues, governmental and political topics,
and finances. All PhD-students involved in
the DPCG also meet once per year informally
to enhance collaboration. They keep close
contacts with each other to exchange ideas
and experiences, and establish efficient logis-
tics and workflow across centers.
The daily management, which includes
social media, a website, and a 3-monthly
newsletter, is done by the DPCG-coordinator
together with PhD-students, supervised by the
scientific committee and DPCG board. Fund-
ing for specific research projects and clinical
trials is obtained via regular funding parties;
theDPCGfunctions as a platform, but does not
provide funding by itself. DPCG specific
activities, such as the salary of the DPCG-
coordinator, are mainly funded through don-
ations of patients and their relatives.
DEVELOPMENT OF
MULTICENTER STUDIES
Since its establishment in 2011, the
DPCG has initiated several multicenter ran-
domized trials, of which 4 have been com-
pleted (PREOPANC-1, LEOPARD-1 and
-2, and CPR).3–5 Currently, 4 multicenter
randomized trials are ongoing; PELICAN
(NTR5517), PREOPANC-2 (NTR7292),
PORSCH (NCT03400280), and PACAP-1
(NCT03513705). A study is listed as a
‘‘DPCG study’’ when at least three DPCG
centers participate but mostly the vast major-
ity of centers participate.
Besides multicenter randomized con-
trolled trials, several nationwide prospective
data registries exist which collaborate under
the umbrella of the Dutch PAncreatic CAncer
Project (PACAP, www.pacap.nl).1 PACAP
was established in 2013 with funding from
O.R.B. and M.G.B. shared senior authorship.
Funding was provided by the Dutch Cancer Society
[grant number UVA2013-5842].
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the Dutch Cancer Society (KWF) and con-
tains clinical data, patient-reported outcomes
and biomaterials. Clinical data are collected
within the Netherlands Cancer Registry
and the Dutch Pancreatic Cancer Audit
(DPCA), a mandatory audit in which nearly
150 variables are collected per pancreatic
resection.6 Patient-reported outcomes are
collected from patients with pancreatic or
periampullary carcinoma from almost 50
centers. Biomaterials from resection speci-
mens are collected in the Dutch Pancreas
Biobank (www.pancreasparel.nl) in collabo-
ration with the Parelsnoer Institute which
provides the infrastructure, logistics, and a
legal/ethical framework for nationwide bio-
banking.2
When designing multicenter studies,
the first and foremost advice is to actively
involve all specialties, researchers of several
centers, and patient advocates in an early
stage. This in contrast to the situation where
a small (often monocenter/monodisciplinary)
group designs a trial and convinces other
centers and specialties to participate in
‘‘their’’ trial. The board and scientific com-
mittee stimulate trials for each disease stage
(ie, resectable, locally advanced, metastatic
cancer), and aim to prevent competing trials
although this may occur, especially in case of
small phase I/II trials of innovative therapies.
AUTHORSHIPS
In many collaborative groups, author-
ship is a recurring topic. To maximize trans-
parency, authorship regulations are specified
in detail in each DPCG study protocol, under
the premise that the International Committee
of Medical Journal Editors guidelines are
leading.7 Authors are identified from each
participating center already during the design
phase of the protocol to allow for broad dis-
cussion and input. Naturally, all authors are
also required to deliver input during the study
and during the stage of analyses andwriting of
the manuscript. When a potential author
would not meet the International Committee
of Medical Journal Editors criteria, he/she is
listed as a collaborator. The senior authorship
positions(s) are reserved for the principal
investigator(s). First authorship(s) are usually
for the PhD student(s) who was/were respon-
sible for daily management, data collection
and the first draft of the manuscript. The other
authorships are for the researchers from the
different participating centers and often based
on the number of contributed samples/patients
(eg, 0–50 patients 1 authorship, 50–100
patients 2 authorships, etc); these authors
are usually listed in alphabetical order.
DIFFICULTIES AND MISTAKES
Over the years we experienced a lot of
difficulties and clearly made several mis-
takes. Also within our group, competition
between centers has been an issue. We feel
that there is no simple solution. To prevent
discussions on authorships, we define author-
ship positions in great detail in the study
protocol, before the actual start of a study.
Also, to prevent discussions on positions in
boards and committee; regular rotations of
board and committee positions (and prede-
fined periods) helps to overcome these issues.
Also, a culture in which these kind of feelings
(eg, a center feels disadvantaged) can
openly be discussed eventually improves
collaboration.
Funding is one of the most important
ongoing problems. The principal investigator
of each DPCG study is responsible for
obtaining sufficient funding through regular
channels. Because of the collaboration and
steady results over the years, the DPCG as a
group has become more interesting for fund-
ing parties. Moreover, because of the already
established logistics, we aim to perform trials
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FIGURE 1. Organizational structure of the Dutch Pancreatic Cancer Group.
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more efficiently (and less costly) using the
‘‘trials within cohorts’’ design in the PACAP
cohort and ‘‘registry-based randomized tri-
als’’ within the DPCA.8 We hope that these
developments will secure our position to
perform clinically relevant randomized trials
in years to come.
AMBASSADOR’S ROLE
Apart from scientific activities, a
nationwide study group will automatically
receive an ‘‘ambassador’s role’’ and become
involved in education. For instance during
the introduction of new (surgical) techniques
a centrally coordinated initiative for safe
implementation could have a strong effect
on quality control. As an example, the DPCG
initiated the LAELAPS projects for safe
implementation of laparoscopic and robotic
pancreatic surgery.9,10 The DPCG also plays
a central role in overseeing several aspects of
clinical care. For example, after the LEOP-
ARD-2 trial questions were raised about the
safety of laparoscopic pancreatoduodenec-
tomy, after which all DPCG surgeons decided
to stop performing these procedures in the
Netherlands. The DPCG facilitates and par-
ticipates in the development of nationwide
guidelines on pancreatic cancer and coordi-
nates a nationwide expert panel. The DPCG
also (co-)organizes several scientific and
social activities, and functions as a point of
contact for those interested in organizing
pancreatic cancer-related activities in (col-
laboration with) the Netherlands.
THE FUTURE
For the future, advanced trial logistics
and sustaining financial support are probably
the most relevant challenges. To face these
challenges, the DPCG is working with novel
trial designs; multiple parallel ‘‘trials within
cohorts’’ in the PACAP cohort,1,8 ‘‘registry-
based randomized trials’’ within the DPCA,
and ‘‘stepped-wedge’’ trials for implementation
of new standards of care. Additionally, it may
soon be impossible to runmulticenter trials in a
single country because of the growing required
sample sizes (less incremental yield due to
continuously improving outcomes). This devel-
opment may drive further international collab-
oration between multicenter study groups. For
example, the DPCG endorses the European
Consortium on Minimally Invasive Pancreatic
Surgery (www.e-mips.com) which is running
the DIPLOMA trial (ISRCTN44897265), and
has joined forces with the German StuDoq
registry on pancreatic surgery. These types of
collaborations are likely to provide a further
quality impulse in the coming years and are
welcomed by the DPCG.
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